首页> 美国卫生研究院文献>Scientific Reports >Nobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells
【2h】

Nobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells

机译:Nobiletin增强ABCB1过表达癌细胞中化疗药物的功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Multidrug resistance (MDR) is the major obstacle to the successful chemotherapy treatment of many cancers. Here we found that nobiletin, a citrus methoxyflavone, significantly sensitized ABCB1 overexpressing cells A2780/T and A549/T to chemotherapeutic agents such as paclitaxel (a 433-fold reversal of MDR to PTX at 9 μM), doxorubicin (DOX), docetaxel and dounorubicin. Nobiletin profoundly inhibited ABCB1 transporter activity since it significantly increased the intracellular accumulation of DOX and Flutax-2 in A2780/T cells and decreased the efflux of ABCB1 substrates in Caco2 cells without altering the mRNA and protein expression of ABCB1. Moreover, nobiletin stimulated ATPase activity and inhibited verapamil-stimulated ATPase activity in a concentration-dependent manner, indicating a direct interaction with the transporter. Consistent with these findings, molecular docking analysis also identified favorable binding of nobiletin with the transmemberane region site 1 of homology modeled human ABCB1 transporter. Moreover, the Nrf2 protein expression and phosphorylation levels of AKT/ERK were suppressed by co-treated with nobiletin and PTX at the reversal concentrations, suggesting that inhibition of the AKT/ERK/Nrf2 pathway was associated with the sensitizing effect of nobiletin. These findings encourage further animal and clinical MDR studies with the combination therapy of nobiletin and chemotherapeutic drugs.
机译:多药耐药性(MDR)是许多癌症成功进行化学疗法治疗的主要障碍。在这里,我们发现诺贝列汀(一种柑橘类甲氧基黄酮)使过表达的ABCB1细胞对A2780 / T和A549 / T细胞明显敏感,例如紫杉醇(紫杉醇(在9μm时MDR逆转为PTX的433倍)),阿霉素(DOX),多西他赛和杜柔比星。 Nobiletin显着抑制ABCB1转运蛋白活性,因为它显着增加了A2780 / T细胞中DOX和Flutax-2的细胞内积累,并降低了Caco2细胞中ABCB1底物的外排,而没有改变ABCB1的mRNA和蛋白表达。此外,诺比列汀以浓度依赖性方式刺激ATPase活性并抑制维拉帕米刺激的ATPase活性,表明与转运蛋白直接相互作用。与这些发现一致,分子对接分析还确定了诺比列汀与同源建模的人ABCB1转运蛋白的跨膜区位点1的有利结合。此外,在逆转浓度下与诺比列汀和PTX共同处理可抑制AKT / ERK的Nrf2蛋白表达和磷酸化水平,这表明对AKT / ERK / Nrf2途径的抑制与诺比列汀的敏化作​​用有关。这些发现鼓励诺比列汀与化学治疗药物联合治疗进一步的动物和临床MDR研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号